Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Barrett

Showing results (41-50 of 349) with videos related to

Pageof 35
Sort By:
Blood|January 4, 2014
STAT3: the "Achilles" heel for AML?Katayoun Rezvani, John Barrett
Expert Review of Hematology|November 19, 2010
Relapse after allogeneic stem cell transplantationA John Barrett, Minoo Battiwalla
The New England Journal of Medicine|July 31, 2009
Genetic trickery--escape of leukemia from immune attackJohn Barrett, Bruce R Blazar
Immunotherapy|April 20, 2012
T-cell therapy for cancerJohn Barrett, Catherine M Bollard
Pediatric Hematology and Oncology|July 16, 2013
Response to the letter: allogeneic hematopoietic stem cell transplantation for treatment of Gaucher diseaseSawa Ito, A John Barrett
Blood|January 3, 2015
ST2: the biomarker at the heart of GVHD severitySawa Ito, A John Barrett
Annual Review of Medicine|January 30, 2004
Nonmyeloablative allogeneic immunotherapy for solid tumorsRichard W Childs, John Barrett
Best Practice & Research. Clinical Haematology|September 16, 2008
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantationKatayoun Rezvani, A John Barrett
Pediatric Hematology and Oncology|February 1, 2013
Gauchers disease--a reappraisal of hematopoietic stem cell transplantationSawa Ito, A John Barrett
Haematologica|April 2, 2009
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevanceA John Barrett, Elaine Sloand
Pageof 35

Showing results (41-50 of 349) with videos related to

Sort By:
Pageof 35
Blood|January 4, 2014
STAT3: the "Achilles" heel for AML?Katayoun Rezvani, John Barrett
Expert Review of Hematology|November 19, 2010
Relapse after allogeneic stem cell transplantationA John Barrett, Minoo Battiwalla
The New England Journal of Medicine|July 31, 2009
Genetic trickery--escape of leukemia from immune attackJohn Barrett, Bruce R Blazar
Immunotherapy|April 20, 2012
T-cell therapy for cancerJohn Barrett, Catherine M Bollard
Pediatric Hematology and Oncology|July 16, 2013
Response to the letter: allogeneic hematopoietic stem cell transplantation for treatment of Gaucher diseaseSawa Ito, A John Barrett
Blood|January 3, 2015
ST2: the biomarker at the heart of GVHD severitySawa Ito, A John Barrett
Annual Review of Medicine|January 30, 2004
Nonmyeloablative allogeneic immunotherapy for solid tumorsRichard W Childs, John Barrett
Best Practice & Research. Clinical Haematology|September 16, 2008
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantationKatayoun Rezvani, A John Barrett
Pediatric Hematology and Oncology|February 1, 2013
Gauchers disease--a reappraisal of hematopoietic stem cell transplantationSawa Ito, A John Barrett
Haematologica|April 2, 2009
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevanceA John Barrett, Elaine Sloand
Pageof 35